Edgewise Therapeutics Shares Outstanding History (EWTX)
Edgewise Therapeutics reported 106.2M shares outstanding at the end of fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 106.2M | 11.4M | +12.03% |
| 2024 | 2024-12-31 | 94.8M | 24.4M | +34.61% |
| 2023 | 2023-12-31 | 70.5M | 7.2M | +11.38% |
| 2022 | 2022-12-31 | 63.3M | 13.8M | +27.79% |
| 2021 | 2021-12-31 | 49.5M | 48.5M | +4803.55% |
| 2020 | 2020-12-31 | 1.0M | — | — |
Edgewise Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 107.8M | 2.4M | +2.31% |
| Q1 2026 | 2026-03-31 | 107.5M | 12.3M | +12.89% |
| Q4 2025 | 2025-12-31 | 106.2M | 11.4M | +12.03% |
| Q3 2025 | 2025-09-30 | 105.8M | 11.4M | +12.03% |
| Q2 2025 | 2025-06-30 | 105.3M | 11.7M | +12.49% |
| Q1 2025 | 2025-03-31 | 95.2M | 1.9M | +2.06% |
| Q4 2024 | 2024-12-31 | 94.8M | 24.4M | +34.61% |
| Q3 2024 | 2024-09-30 | 94.4M | 30.9M | +48.77% |
| Q2 2024 | 2024-06-30 | 93.6M | 30.2M | +47.57% |
| Q1 2024 | 2024-03-31 | 93.3M | 30.0M | +47.43% |
| Q4 2023 | 2023-12-31 | 70.5M | 7.2M | +11.38% |
| Q3 2023 | 2023-09-30 | 63.5M | 252,111 | +0.40% |
| Q2 2023 | 2023-06-30 | 63.5M | 13.7M | +27.48% |
| Q1 2023 | 2023-03-31 | 63.3M | 13.7M | +27.68% |
| Q4 2022 | 2022-12-31 | 63.3M | 13.8M | +27.79% |
| Q3 2022 | 2022-09-30 | 63.2M | 13.9M | +28.22% |
| Q2 2022 | 2022-06-30 | 49.8M | 518,370 | +1.05% |
| Q1 2022 | 2022-03-31 | 49.6M | 301,995 | +0.61% |
| Q4 2021 | 2021-12-31 | 49.5M | 48.5M | +4803.55% |
| Q3 2021 | 2021-09-30 | 49.3M | — | — |
| Q2 2021 | 2021-06-30 | 49.3M | — | — |
| Q1 2021 | 2021-03-31 | 49.3M | — | — |
| Q4 2020 | 2020-12-31 | 1.0M | — | — |
Edgewise Therapeutics shares outstanding trends
Over the last five reported fiscal years, Edgewise Therapeutics's shares outstanding moved from 1.0M to 106.2M, a change of 105.2M. The latest reported quarter, Q2 2026, shows 107.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics filings at SEC.gov ↗